Contraindications
- CrCl 59 mL/min or less
- History of NSAID-related gastrointestinal bleeding, perforation or ulcer; active peptic ulcer
- Severe heart failure
- Severe hepatic impairment (Child-Pugh 10–15)
- Bleeding disorders; inflammatory bowel disease
- Severe dehydration
- Third trimester of pregnancy; breastfeeding
- NSAID hypersensitivity (asthma, urticaria)
Dosing: Adult
- Acute mild to moderate pain (adults): 25 mg every 8 hours; maximum 75 mg/day; shortest duration
- Older adults, mild–moderate hepatic impairment, CrCl 60–89: Start at 50 mg/day total
- Acute moderate to severe pain, injection (IV or IM): 50 mg every 8 to 12 hours (may repeat after 6 hours if needed); maximum 150 mg/day; no more than 2 days. CrCl 60–89: 50 mg/day total; CrCl ≤59: contraindicated
Dosing: Altered kidney function
Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) excreted mainly in urine as glucuronide. NSAIDs can cause fluid retention, hyperkalemia and acute kidney injury. The Irish label starts at 50 mg/day in mild kidney impairment (creatinine clearance [CrCl] 60–89 mL/min) and contraindicates it at CrCl 59 mL/min or below. It has no US FDA label.
Kidney function measure: Irish summary of product characteristics (SmPC) uses creatinine clearance (CrCl, mL/min); thresholds 89 and 59.
Show full dosing details
- CrCl ≥60 mL/min
- CrCl ≥90: 25 mg every 8 hours, maximum 75 mg/day, shortest course. CrCl 60–89: start at 50 mg/day total (SmPC). Injection: 50 mg every 8 to 12 hours, maximum 150 mg/day, no more than 2 days; CrCl 60–89: 50 mg/day total (injection SmPC).
- CrCl 30–59 mL/min
- Contraindicated: moderate to severe kidney dysfunction (CrCl ≤59 mL/min) (oral and injection SmPCs).
- CrCl 15–29 mL/min
- Contraindicated: moderate to severe kidney dysfunction (CrCl ≤59 mL/min) (oral and injection SmPCs).
- CrCl <15 mL/min (not on dialysis)
- Contraindicated: moderate to severe kidney dysfunction (CrCl ≤59 mL/min) (oral and injection SmPCs).
- Hemodialysis (intermittent)
- Contraindicated (CrCl ≤59; SmPC).
- Peritoneal dialysis
- Contraindicated (CrCl ≤59; SmPC). NSAIDs also hasten loss of residual kidney function.
- CRRT
- Contraindicated (CrCl ≤59; SmPC); NSAIDs worsen acute kidney injury.
- Dialyzable? Not stated (99% protein-bound).
- Monitoring Kidney function, potassium and fluid status, especially with diuretics, ACE inhibitors, ARBs or volume depletion; keep the patient hydrated. Gastrointestinal bleeding. Shortest course (SmPC 4.4).
Children (kidney dosing)
- eGFR ≥60
- Not established in children; kidney dosing not applicable.
- eGFR 30–59
- Not established in children; kidney dosing not applicable.
- eGFR 15–29
- Not established in children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not established in children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not established in children; kidney dosing not applicable.
- Peritoneal dialysis
- Not established in children; kidney dosing not applicable.
- CRRT
- Not established in children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: HPRA (Ireland) product information (April 2023). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Not to be used in children and adolescents (SmPC).
- Usual dose
- Not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Film-coated tablet: 25 mg
- ) solution for injection: 25 mg/mL (50 mg/2 mL
- Solution for injection: 25 mg/mL
- Tablet: 25 mg
- ) solution for injection or concentrate for infusion: 25 mg/mL (50 mg/2 mL
- Granule for oral solution: 25 mg
Registered products in the Philippines
20 products registered with the Food and Drug Administration (FDA) Philippines list Dexketoprofen as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products20
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
DalyxDexketoprofen (as trometamol) | 50 mg/2 mL Solution For Injection or Concentrate For Solution For Infusion (IV/IM)Type I amber glass ampoule with break ring x 2 mL (Box of 5's) | Rx | Rompharm Company SRLRomania | The Cathay Drug Co., Inc.Importer: I.E. Medica, Inc. | DR-XY46849 | Mar 11, 2031 | |
DeccetrolDexketoprofen (As Trometamol) | 25mg/mL Solution For Injection (IM/IV)Type I amber ampoule x 2 mL (Box of 6's) | Rx | Osel Ilac San Ve Tic A.S.Turkey | Accesspoint International Trading Inc.Importer: Accesspoint International Trading, Inc. | DRP-14214 | Jul 27, 2028 | |
DexoflamDexketoprofen (as trometamol) | 25 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 10's, 30's & 100's) | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-17814 | Mar 12, 2031 | |
DexomolDexketoprofen (as trometamol) | 25 mg Film-Coated TabletOpaque White PVC/PE/PVDC Aluminum Foil Blister Pack x 10's (Box 20's) | Rx | Santa Farma İlaç Sanayii A.Ş.Turkey | Orange Biotec Inc. | DRP-15704 | Aug 29, 2029 | |
DexprokenDexketoprofen (as Trometamol) | 25 mg/mL (50 mg/2 mL) Solution For Injection (IM/IV)2 mL USP Type I amber glass ampoule (Box of 6's) | Rx | İdol İlaç Dolum San. Ve Tic. A.Ş.Turkey | Importer: Ambicare Pharmaceuticals, Inc.Trader: Helba İlaç Ic ve Dis Sa. Tic. A.Ş. | DRP-13850 | May 5, 2028 | |
DitroxDexketoprofen (as trometamol) | 25 mg/mL (50 mg/2 mL) Solution for Injection (I.M./I.V.)USP Type 1 amber glass ampoule x 2 mL (Box of 10's) | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-17118 | Oct 1, 2030 | |
ElpidexDexketoprofen (as trometamol) | 25 mg / mL Solution for Injection (IM/IV)Type I amber ampoule x 2 mL (Box of 6's) | Rx | Osel Ilac San. Ve Tic. A.S.Turkey | Elpizo Holdings IncImporter: Accesspoint International Trading Inc. | DRP-14214-01 | Jul 27, 2028 | |
Infen-25Dexketoprofen (as trometamol) | 25 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Emcure Pharmaceuticals LimitedIndia | Emcure Pharma Philippines Inc. | DR-XY45922 | Jun 14, 2027 | |
Infen-25Dexketoprofen (as trometamol) | 25mg Film -Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Emcure Pharmaceuticals LimitedIndia | Emcure Pharma Philippines Inc. | DRP-16550 | Jun 14, 2027 | |
KeprofynDexketoprofen (as trometamol) | 25 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-14656 | Nov 17, 2028 | |
KeralDexketoprofen (as trometamol) | 25 mg/mL (50 mg/2 mL) Solution for Injection or Concentrate for Solution for Infusion (I.M./I.V.)2 mL Type I Amber Glass Ampoule (Box of 1’s and 5’s) | Rx | A. Menarini Manufacturing Logistics and Services SRLItaly | A. Menarini Philippines, Inc. | DR-XY36227 | Jul 13, 2029 | |
KetesseDexketoprofen (as trometamol) | 25 mg Granules for Oral Solution2.5 g sachet (aluminum-polyethylene) Box of 4's, 10's and 20's | Rx | Laboratorios Menarini, SASpain | A. Menarini Philippines, Inc.Trader: A. Menarini Asia-Pacific Holdings Pte. Ltd. | DR-XY46140 | Nov 9, 2027 | |
KetesseDexketoprofen (as Trometamol) | 25mg Film-Coated TabletAlu/Alu (PA/Aluminum/PVC/Aluminum) Blister Pack x 10's (Box of 20's) | Rx | A. Menarini Manufacturing Logistics and Services S.R.L.Italy | Importer: A. Menarini Philippines, Inc. | DR-XY36275 | May 29, 2027 | |
KetesseDexketoprofen (as trometamol) | 25mg/mL (50mg/2mL) Solution for Injection or Concentrate for Infusion (I.M./I.V)2 mL Type I Amber glass ampoule (Box of 1’s); 2 mL Type I Amber glass ampoule (Box of 5’s) | Rx | A. Manerini Manufacturing Logistics and Services S.R.L.Italy | A.MENARINI PHILIPPINES, INC | DR-XY36266 | Jul 17, 2029 | |
KetofenaxDexketoprofen (as trometamol) | 50mg/2mL Solution for Injection or Concentrate for Solution for Infusion (I.V./I.M.)Type I Amber Glass Ampoule with Break Ring x 2 mL (Box of 5's and 10's) | Rx | S.c Rompharm Company S.R.L.Romania | I.E. Medica, Inc. | DR-XY46848 | Mar 11, 2027 | |
KeviaDexketoprofen | 25 mg/mL (50 mg/2 mL) Solution for Injection or Concentrate for Solution for Infusion (I.M./I.V.)USP Type I Amber Coloured Glass Ampoule x 2 mL (Box of 1’s, 5’s and 10’s) | Rx | Ciron Drugs & Pharmaceuticals Pvt. Ltd.India | Despina Pharma Inc. | DRP-18941 | Oct 5, 2031 | |
MetademDexketoprofen Trometamol | 25 mg/mL (50 mg/2 mL) Solution for Injection (IM/IV)2 mL Type I amber colored Glass ampoules (Box of 6's) | Rx | VEM Ilac San. Ve Tic A.S.Turkey | Macropharma Corparation | DRP-14332 | Aug 22, 2028 | |
ProfiemDexketoprofen (as Trometamol) | 25 mg TabletAlu-Alu Blister pack x 10's (Box of 20's) | Rx | Novagen Healthcare Private LimitedIndia | I.E Medica, Inc. | DRP-15811 | Sep 17, 2029 | |
VoxibDexketoprofen (as trometamol) | 25 mg/ml Solution for Injection (1. M./1.V.) or Concentrate for Solution for I. V. Infusion2 mL (net content) Ph. Eur. Type I amber glass ampoule X 5 ampoules in transparent PVC tray (Box of 5 ampoules) | Rx | PT. Novell Pharmaceutical LaboratoriesIndonesia | Prosweal Healthcare, Inc. | DR-XY48077 | Jun 1, 2027 | |
(no brand name)Dexketoprofen (as Trometamol) | 25 mg TabletAlu-Alu Blister pack x 10's (Box of 20's) | Rx | Novagen Healthcare Private LimitedIndia | I.E Medica, Inc. | DRP-15812 | Sep 17, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Other NSAIDs, COX-2 inhibitors, salicylates 3 g/day or more | Avoid | More gastrointestinal ulceration and bleeding. | Do not combine. |
| Warfarin, heparins | Adjust or monitor | More bleeding. | Avoid if possible; otherwise monitor closely. |
| Diuretics, ACE inhibitors, ARBs, aminoglycosides | Adjust or monitor | Less blood-pressure effect; kidney deterioration. | Hydrate; monitor kidney function. |
| Potassium-sparing diuretics | Adjust or monitor | Hyperkalemia. | Monitor potassium. |
| Methotrexate | Avoid | Hematologic toxicity. | Avoid at 15 mg/week or more; weekly blood counts at lower doses. |
| Lithium | Adjust or monitor | Higher lithium levels. | Monitor lithium. |
| Corticosteroids, SSRIs, antiplatelets | Adjust or monitor | More gastrointestinal bleeding. | Use with caution. |
| Tenofovir, zidovudine, pemetrexed | Adjust or monitor | Nephrotoxicity (tenofovir); anemia (zidovudine); pemetrexed toxicity. | Monitor kidney function or blood counts; avoid around pemetrexed doses. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Nausea, vomiting
- Abdominal pain, diarrhea, dyspepsia
Serious
- Peptic ulcer, gastrointestinal bleeding or perforation
- Acute kidney failure, nephritis, nephrotic syndrome
- Anaphylaxis
- Stevens-Johnson syndrome, toxic epidermal necrolysis
- Neutropenia, thrombocytopenia
Monitoring parameters
- Kidney function, potassium and fluid status, especially with diuretics, ACE inhibitors, ARBs or volume depletion; keep the patient hydrated. Gastrointestinal bleeding. Shortest course (SmPC 4.4). Kidney
- Kidney function, potassium and blood pressure in at-risk patients
- Gastrointestinal bleeding
Pharmacokinetics
Key PK parameters
| Time to peak | 15 to 20 minutes (oral solution) |
|---|---|
| Half-life | 1.65 hours |
| Volume of distribution | Under 0.25 L/kg |
| Protein binding | 99% |
| Metabolism (CYP, transporters) | Glucuronide conjugation (no inversion to R-enantiomer) |
| Renal excretion kidney | Mainly renal as glucuronide (percentage not stated) |
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Health Products Regulatory Authority (Ireland). Keral 25 mg oral solution in sachet SmPC (PA0865/002/006) [HPRA (Ireland) product information, April 2023; no US FDA label]. https://assets.hpra.ie/products/Human/22403/Licence_PA0865-002-006_05042023153747.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Menarini International Operations Luxembourg S.A.. (2023). Keral 25 mg oral solution in sachet (dexketoprofen) [Summary of product characteristics, licence PA0865/002/006; text revised April 2023]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/22403/Licence_PA0865-002-006_05042023153747.pdf
- AS Kalceks. (2026). Morsadex 50 mg/2 mL solution for injection/infusion (dexketoprofen) [Summary of product characteristics, licence PA2165/002/001; text revised May 2026]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/30409/Licence_PA2165-002-001_06052026140647.pdf
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .